Concepedia
Statistics
Publications
5
Citations
311
H-Index
Active since
1990
Affiliations
Wellcome Sanger Institute(Current)
AstraZeneca (Singapore)
AstraZeneca (United Kingdom)
Kyoto University
AstraZeneca (Germany)
Shanade Dunn is an author at Wellcome Sanger Institute specializing in medicine, molecular oncology, and oncology.
Publications per year
1990–2024
ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response
Sankari Nagarajan, Shalini V. Rao, Joseph E. Sutton et al. · Nature Genetics · 2020 · 181 citations · Full text
Medicine, Cancer Biology, Oncology +12
Measurement of activity of urea resistant neutrophil alkaline phosphatase as an antenatal screening test for Down's syndrome.
Howard Cuckle, Nicholas Wald, S. Goodburn et al. · BMJ · 1990 · 47 citations · Full text
Medicine, Maternal Health, Obstetrics +15
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
Shanade Dunn, Cath Eberlein, Jason Yu et al. · Oncogene · 2022 · 34 citations · Full text
Medicine, Oncology, Pharmacology +17
Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer
Matthias Pfeifer, Jonathan Brammeld, Stacey Price et al. · Communications Biology · 2024 · 30 citations · Full text
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer
Cath Eberlein, Stuart C. Williamson, Lorna Hopcroft et al. · British Journal of Cancer · 2024 · 19 citations · Full text
Medicine, Oncology, Pharmacology +15
1–5 of 5